BRNS fundamentals
An in-depth look to Barinthus Biotherapeutics plc operating, investing, and financing activities
BRNS free cash flow for Q1 24 is -12.12 M USD. For 2023, BRNS free cash flow was -56.56 M USD and operating cash flow was -51.12 M USD.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM